Home / Lose weight / Medication / Orforglipron

Orforglipron tablets

Effects, Study Data, Oral Administration and Current Regulatory Status

dr nicolette lammers the body clinic

This page has been reviewed by
Dr. Nicolette Lammers.

What is Orforglipron?

Orforglipron is an oral investigational medication containing the active ingredient orforglipron. The drug is currently being studied in clinical trials for the treatment of obesity, overweight with weight-related comorbidities, and type 2 diabetes. Orforglipron belongs to the class of GLP-1 receptor agonists and differs from many other medications in this class in that it is taken as a tablet.

Its oral use is especially relevant: orforglipron is being studied as a once-daily tablet rather than as an injection. Early phase 3 results are considered promising. However, the current regulatory classification is important: orforglipron is not yet regularly approved in Germany or in the European Union. The Body Clinic does not currently prescribe orforglipron.

If you are interested in treatment options that are currently available, you can find more information about weight loss with tablets as well as on our page about Rybelsus. If you are interested in already available alternatives for medical weight loss, you can also find more information on our pages about Wegovy and Mounjaro.

If you would like a medical assessment of currently available treatment options, you can get advice at our locations or nationwide online via video consultation.

Inhalt
    Add a header to begin generating the table of contents

    Who is Orforglipron suitable for?

    Orforglipron is currently not a regularly available medication in Germany, but an active ingredient that is still undergoing regulatory evaluation for this market. In clinical trials, orforglipron has been studied, among other things, in adults with obesity, in adults with overweight and weight-related comorbidities, and in adults with type 2 diabetes.

    Whether orforglipron will eventually be approved in Germany or in the European Union for specific patient groups depends on decisions by regulatory authorities. For an individual medical assessment, not only weight and body mass index are relevant, but also comorbidities, concurrent medication, tolerability, and the specific treatment goal.

    What is Orforglipron approved for?

    In Germany and in the European Union, orforglipron is currently not regularly approved. At present, there is no regulator-approved standard use in routine clinical care and no regular prescribing option. This classification is also important for patients in Germany: The Body Clinic does not currently prescribe orforglipron.

    If you are interested in treatment options that are already available, you can find more information about medical weight loss with tablets, Rybelsus, Wegovy, and Mounjaro.

    How does Orforglipron work?

    Orforglipron belongs to the group of GLP-1 receptor agonists. The active ingredient activates GLP-1 receptors and can therefore influence appetite, satiety, gastric emptying, and blood sugar regulation, among other things. Its basic mechanism of action is similar to that of other GLP-1-based medications, but it differs in that it is an orally administered small-molecule drug.

    Based on current scientific understanding, orforglipron may help reduce calorie intake and support glucose metabolism. In phase 3 trials, clinically meaningful effects on weight and metabolic parameters were observed in both obesity and type 2 diabetes. However, such study data are not equivalent to regular approval in Germany and do not represent a fixed expectation for an individual patient.

    How is Orforglipron used?

    Orforglipron is taken as a tablet. In the studies conducted so far, the active ingredient has been investigated as an oral medication taken once daily. Unlike some other oral GLP-1 therapies, orforglipron was studied without fixed requirements regarding food or water intake.

    Use in clinical trials

    Different dose strengths were investigated in the clinical trials. The active ingredient was dose-escalated gradually in order to improve tolerability. However, such study regimens are not equivalent to an approved standard therapy in Germany and should not be understood as a basis for independent use.

    Your Journey to Sustainable Weight Loss Starts Here.

    Check your eligibility

    Who developed Orforglipron?

    Manufacturer

    Orforglipron is being developed by Eli Lilly. The active ingredient belongs to the newer pharmacologic approaches in obesity and type 2 diabetes and is part of the GLP-1 receptor agonist class. Unlike many other active ingredients in this class, orforglipron is being studied as a tablet rather than as an injection.

    Availability in Germany

    Orforglipron is currently not regularly approved in Germany and is not available in routine clinical care. For patients in Germany, one point is important: The Body Clinic does not currently prescribe orforglipron. If you are interested in treatment options that are already available, you can find more information on our pages about Rybelsus, Wegovy, and Mounjaro.

    Where can I buy Orforglipron?

    Orforglipron is currently not available over the counter in Germany and is not regularly available through pharmacies. It should not be obtained independently. The Body Clinic does not currently offer orforglipron and does not prescribe it at this time.

    Which medication options are actually available at present and may be medically appropriate in an individual case should always be assessed by a physician. You can find an overview of our currently available programs on our page Prices for medical weight loss.

    What are the possible side effects?

    The phase 3 data published so far mainly show gastrointestinal symptoms as common side effects. These occurred especially during dose escalation and are broadly consistent with the known side effect profile of other GLP-1-based therapies.

    • Nausea
    • Constipation
    • Diarrhea
    • Vomiting
    • Dyspepsia

    In the published study data, these symptoms were described predominantly as mild to moderate. Orforglipron continues to be evaluated in clinical studies and regulatory procedures. For that reason, it is important not to view the active ingredient as a regularly available treatment in Germany at this time.

    When should medical advice be sought?

    Because orforglipron is currently not a regularly approved medication for routine clinical care in Germany, it should not be used independently outside regulated medical settings. Regardless of that, severe or persistent symptoms such as intense abdominal pain, repeated vomiting, significant fluid loss, or symptoms that worsen rapidly should always be medically assessed promptly.

    Safety, interactions, and contraindications

    At present, there is no regularly approved prescribing information for orforglipron for routine clinical use in Germany. This also means that there is no regulator-approved standard use, no dosage recommendations established for routine care in Germany, and no contraindications that have been definitively established for patients outside clinical trials.

    Based on current knowledge, the active ingredient continues to be studied for efficacy and safety. As with other GLP-1-based medications, gastrointestinal symptoms, tolerability during dose escalation, and possible effects on metabolic parameters may be relevant. Independent use or procurement should therefore not occur.

    Pregnancy and breastfeeding

    During pregnancy and breastfeeding, orforglipron should not currently be used independently in Germany. Because the active ingredient is not yet regularly approved for this market, patients planning a pregnancy should also rely on alternatives that are already approved and medically evaluated.

    Medical Weight Loss in Berlin, Munich, Hamburg, Frankfurt, or online.

    Our Locations

    How does Orforglipron differ from other medications?

    The key difference lies not only in the active ingredient, but above all in the dosage form and regulatory status. Orforglipron is an oral GLP-1 receptor agonist taken as a tablet. In Germany and the European Union, the active ingredient is not yet regularly approved. This distinguishes orforglipron from already available medications for weight loss or diabetes treatment that can already be used in routine clinical care.

    Currently available medications such as Rybelsus, Wegovy, or Mounjaro can already be medically assessed and are regularly available. Orforglipron, by contrast, is still being discussed as a future treatment option for the German market and is not currently prescribed by The Body Clinic.

    Orforglipron vs. Rybelsus

    Rybelsus contains semaglutide and is an already available oral GLP-1 medication. Orforglipron is also a tablet-based therapy, but it contains a different active ingredient. Another difference lies in the regulatory situation: Rybelsus is already approved and can be medically assessed, whereas orforglipron is not yet regularly approved in Germany.

    Orforglipron vs. Wegovy

    Wegovy contains semaglutide and is administered as an injection. Orforglipron, by contrast, is being studied as a tablet. Both active ingredients target the GLP-1 receptor, but they differ significantly in dosage form and in their regulatory status for Germany.

    Orforglipron vs. Mounjaro

    Mounjaro contains tirzepatide and acts on GIP and GLP-1 receptors. Orforglipron, by contrast, acts as a GLP-1 receptor agonist. The mode of administration also differs: Mounjaro is used as a once-weekly injection, whereas orforglipron is being studied as a tablet. This means the two medications differ in both mechanism of action and use.

    Is Orforglipron covered by health insurance?

    Orforglipron is currently not regularly approved or regularly available in Germany. For that reason alone, reimbursement in routine care is not currently to be expected. Independently of that, medications used for weight loss, appetite suppression, or the regulation of body weight are generally excluded from statutory health insurance coverage in Germany.

    If you would like to learn more about currently available and actually prescribable options, you can find an overview on our page Prices for medical weight loss.

    How can I stop taking Orforglipron?

    Because orforglipron is currently not a regularly approved medication for routine clinical use in Germany, there is no established everyday medical standard recommendation for discontinuation, unlike with medications that are already approved. If orforglipron is used as part of a clinical trial, any changes, pauses, or discontinuation should take place only after consultation with the responsible study team.

    It is also important to note that orforglipron should not be obtained independently or used outside regulated medical settings. If use has already occurred and there are symptoms, uncertainties, or questions about how to proceed, this should be discussed with a physician promptly. You can find an overview of currently available medically supervised programs under medical weight loss.

    Frequently asked questions about Orforglipron

    Orforglipron is currently not regularly approved in Germany or in the European Union. There is currently no regular prescribing option for the German market. In the United States, orforglipron was approved in April 2026 under the brand name Foundayo, but that approval does not apply to Germany.
    Not as a regular treatment option at this time. In Germany, orforglipron is not currently available through routine pharmacy channels, so it should not be independently obtained.
    Orforglipron is an oral GLP-1 receptor agonist taken as a tablet. The active ingredient is being studied for the treatment of obesity, overweight with comorbidities, and type 2 diabetes, and it is already partly marketed outside Europe.
    Orforglipron is taken as a tablet. In clinical trials and in the U.S. approval, it is described as a once-daily oral medication. An important difference from some other oral GLP-1 therapies is that, according to Lilly, it can be taken without specific food or water restrictions.
    Orforglipron acts as a GLP-1 receptor agonist. It can influence appetite, satiety, gastric emptying, and blood sugar regulation. Its basic mechanism is similar to other GLP-1-based medications, but the tablet form is an important difference.
    Clinically meaningful weight reduction has been reported in published studies and phase 3 results. However, those study data are not a fixed expectation for an individual patient and do not replace regular approval or medical assessment in Germany.
    So far, the main reported side effects have been gastrointestinal symptoms. These include nausea, constipation, diarrhea, vomiting, and dyspepsia. In the published data, these side effects were described predominantly as mild to moderate and were observed especially during dose escalation.
    That cannot be answered in general terms. Orforglipron also works through GLP-1, but it is a tablet and is not yet regularly approved in Germany. Direct comparisons with already available medications such as semaglutide or tirzepatide always need to be interpreted in the specific medical context.
    At present, regular reimbursement in Germany is not to be expected because orforglipron is not yet regularly approved or routinely available there. Independently of that, medications used for weight loss, appetite suppression, or body weight regulation are generally excluded from statutory health insurance coverage in Germany.
    Because orforglipron is currently not a regularly approved standard medication in routine care in Germany, there is no established everyday clinical standard for stopping it there. If the active ingredient is being used as part of a clinical trial or has already been used, any changes or discontinuation should always be discussed with a physician or the responsible study team.

    Sources

    1. Pratt, E., Ma, X., Liu, R. et al. 2023. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes, Obesity and Metabolism. Read study.
    2. Eli Lilly and Company. FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions. Open page.
    3. Eli Lilly and Company. Lilly’s oral GLP-1 orforglipron showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines in complete Phase 3 results published in The New England Journal of Medicine. Read press release.
    4. Eli Lilly and Company. Lilly’s oral GLP-1 orforglipron is successful in the third Phase 3 trial, triggering global regulatory submissions for the treatment of obesity. Read press release.
    5. ClinicalTrials.gov. A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1). Open trial registry.
    6. ClinicalTrials.gov. A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2). Open trial registry.
    7. ClinicalTrials.gov. A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (ACHIEVE-1). Open trial registry.
    8. European Medicines Agency (EMA). Orforglipron: Paediatric Investigation Plan for the treatment of obesity (EMEA-003299-PIP02-22). Open EMA page.
    9. European Medicines Agency (EMA). Orforglipron: Paediatric Investigation Plan for the treatment of type 2 diabetes mellitus (EMEA-003299-PIP01-22). Open EMA page.

    Schedule an Appointment

    Click the button below to book your initial consultation with our medical assistant. We look forward to supporting you on your journey to a healthy weight.
    Check your eligibility
    Scroll to Top